Milk Thistle Dosage for Fatty Liver: Trial Doses

Milk thistle is the most famous "liver herb" on the planet — and for fatty liver (NAFLD) it is also one of the most honestly contested. This guide gives you two things most articles won't: the exact doses the clinical trials used, and a clear-eyed reading of what those trials found — including the federally funded studies that came back negative. No cure claims. Just the doses, the data, and the caveats.

Evidence-Based Guide | Liver Health

About Milk Thistle (Silymarin)

Milk thistle (Silybum marianum) is a tall Mediterranean plant with purple flowers in the daisy family. Its active fraction is silymarin — not a single compound but a standardized mixture of flavonolignans: mainly silybin (also called silibinin, the most studied component), plus silycristine, silydianin, and smaller amounts of taxifolin and quercetin (LactMed, NCBI Bookshelf NBK501771). It has roughly 2,000 years of traditional use for liver complaints, and the German regulatory tradition even registered silymarin as a drug for liver disease in many countries.

The proposed actions — antioxidant, anti-inflammatory, antifibrotic, and liver-cell-regenerating effects — come overwhelmingly from preclinical work (Abenavoli et al., Phytotherapy Research 2018). Silybin's oral bioavailability is low and variable (about 23–47%) and it is rapidly conjugated in the liver, so most of what circulates after a capsule is metabolite, not the molecule on the label.

A Naming Note: NAFLD Is Now Often Called MASLD

In 2023, a multi-society Delphi consensus statement (Rinella ME et al., Hepatology 2023, PMID 37363821) established new terminology: non-alcoholic fatty liver disease (NAFLD) became metabolic dysfunction-associated steatotic liver disease (MASLD), and NASH became MASH. The disease itself didn't change — fat accumulation in the liver tied to metabolic syndrome (obesity, insulin resistance, dyslipidemia) — only the name. Recent literature (e.g., the 2024 meta-analysis cited below) increasingly uses MASLD. This article uses NAFLD/MASLD interchangeably; if you search the literature, search both terms.

The Honest Evidence Picture

This is the section most supplement articles skip. Read it before you buy anything.

The negative trials are the best-designed ones. Two trials funded by NCCIH itself found no benefit:

• *Fried et al. (2012, JAMA) — 154 patients with chronic hepatitis C (not NAFLD, but the highest-quality silymarin trial ever run): silymarin 420 or 700 mg three times daily* for 24 weeks vs placebo. Only 2 patients in each group hit the ALT endpoint; no difference in liver enzymes, virus levels, or quality of life. Doses were 3–5× the customary 140 mg 3×/day.
• *Navarro et al. (2019, PLoS One) — the NASH trial: 78 non-cirrhotic NASH patients randomized to Legalon 420 mg or 700 mg three times daily or placebo for 48 weeks, with liver biopsy before and after. The primary endpoint (≥2-point histological improvement) was reached by 15–19% of silymarin patients vs 12% of placebo — not statistically significant (p=0.79)*. The authors concluded the effect "remains inconclusive."

LiverTox — the NIH's authoritative drug-induced-liver-injury reference — describes silymarin as having "little or no evidence of benefit" on liver-disease activity in the clinical trial record. NCCIH's standing assessment: results in NAFLD/NASH trials have been "conflicting or too limited to allow conclusions."

The positive side is real but weaker. A 2024 meta-analysis (Annals of Hepatology, 26 RCTs, 2,375 patients) found silymarin significantly reduced ALT, AST, total and LDL cholesterol, triglycerides, fasting insulin and HOMA-IR, and improved hepatic steatosis on histology — but the authors' own conclusion was that "the effects of silymarin will need to be confirmed by further research." An earlier 2017 meta-analysis (8 RCTs, 587 patients) found reductions in transaminases. Meta-analyses of small, heterogeneous trials sit below the two big negative RCTs in evidence quality — the honest reading is: encouraging signals in liver enzymes and metabolic markers, no proof of disease modification.

What this means for dosing: silymarin is being dosed for a possible supportive effect on liver enzymes and metabolic markers — not as a treatment for fatty liver disease. Weight loss, diet, and exercise remain the only interventions with solid evidence for NAFLD/MASLD. Milk thistle is an adjunct at best, not a substitute.

Trial Doses vs Label Doses

The key takeaway: 420 mg/day (140 mg 3×) is the evidence-anchored dose — it is what most trials used. Doses above it have been tested and are safe, but the high-dose trials did not produce better efficacy.

Dosage Guide

Doses below are context, not prescriptions. If you have diagnosed fatty liver disease, your dosing conversation should include your doctor — especially since liver disease changes drug metabolism.

Form notes: Buy standardized extract — label should state 70–80% silymarin content. Actual silymarin content varies substantially between brands; prefer third-party-tested products. Take with meals to reduce GI upset and aid the fat-soluble components' absorption.

Forms: Standardized Extract vs Phytosome

Silybin's problem is delivery: low and variable oral bioavailability. The phytosome (silybin-phosphatidylcholine complex, marketed as Silipide/Siliphos) was engineered to fix that, and it has human pharmacokinetic data:

• Barzaghi et al. (1990) — in healthy volunteers, the silybin-phosphatidylcholine complex produced roughly 4–5× greater silybin exposure than plain silymarin (the frequently quoted 4.6× is this study's plasma-based relative oral availability, 4.6 ± 1.5; a later review reports Cmax 298 vs 102 ng/mL and AUC 881 vs 257 ng/mL·h — about a 3× ratio — for 120 mg silybin equivalents). Either way, the bioavailability gain is real and measured in humans.
• The practical consequence: phytosome products are dosed lower — about 100 mg 3×/day of the complex.

Does better absorption mean better results? Not necessarily, and not proven — the clinical trials showing enzyme effects mostly used plain standardized silymarin. Phytosomes are a reasonable choice for getting more silybin per milligram, but don't treat them as clinically proven superior for NAFLD outcomes.

Safety & Interactions

Silymarin is remarkably well tolerated. In the NCCIH-funded trials — including the 2,100 mg/day arms — adverse events did not differ significantly from placebo. The most common complaints are mild gastrointestinal effects (loose stool, bloating, nausea); the site's page notes GI effects above 1,500 mg/day. One review judged it safe at doses up to 1,500 mg/day for treatment durations up to 41 months.

Allergy: Rare allergic reactions, mainly in people allergic to the ragweed/daisy family (Asteraceae) — milk thistle is a member.

Blood sugar: Silymarin may lower blood sugar; people with diabetes or on glucose-lowering drugs should monitor and inform their doctor. (Paradoxically, the one area with positive trial signals for milk thistle is glycemic control in type 2 diabetes — mostly studied in Middle Eastern populations.)

Bile-duct obstruction: Because silymarin may stimulate bile flow, people with gallstones or known or suspected bile-duct obstruction should use milk thistle only under medical supervision (standard choleretic-herb caution; no trial has tested this risk directly).

Pregnancy/breastfeeding: Insufficient data — NCCIH and product guidance advise against use.

Drug interactions: The federal record is thin. LactMed's single pharmacokinetic line says milk thistle might increase the metabolism of some drugs — the opposite of the retail claim that it inhibits CYP450 enzymes. NCCIH gives its standing instruction: talk to your health care provider before combining milk thistle with any medicine. People with liver disease — the most likely users — are frequently on narrow-margin medicines, so this conversation matters more than the interaction data looks.

So What Dose Should You Actually Use?

1. Start with the trial dose: 140 mg silymarin, three times daily with meals (420 mg/day). This is the only dose with a real evidence footprint across dozens of trials.
2. Give it 3–6 months, then check labs. Transaminases and metabolic markers (glucose, lipids) are the endpoints that moved in the positive studies; reassess with your doctor whether continuing makes sense.
3. Don't megadose. The 3–5× "supratherapeutic" arms in the best-designed trials added no benefit. Higher is not better here.
4. Treat it as adjunct, not treatment. For NAFLD/MASLD, weight loss of 7–10% has more evidence behind it than any supplement. Milk thistle sits on top of lifestyle changes, never instead of them.
5. Buy standardized, third-party-tested extract (70–80% silymarin) — and if you choose a phytosome, dose it at ~100 mg 3×/day, not the 140 mg extract dose.

📢 Disclaimer: This information is for educational purposes only and is not medical advice. Always consult a qualified healthcare professional before starting any new supplement. Sources are linked for verification.

Explore the Full Remedy Database

Browse 500+ organic alternatives for health, wellness, and natural living.